These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30136603)

  • 1. Real-world assessment of treatment with extended-release topiramate (Trokendi XR
    O'Neal W; Hur EE; Liranso T; Patel B
    J Comp Eff Res; 2018 Nov; 7(11):1095-1105. PubMed ID: 30136603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations.
    Brittain ST; Wheless JW
    Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topiramate in Migraine Prevention: A 2016 Perspective.
    Silberstein SD
    Headache; 2017 Jan; 57(1):165-178. PubMed ID: 27902848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of extended-release topiramate in patients with epilepsy: A two-year retention study.
    Lee H; Kim DW
    J Clin Pharm Ther; 2021 Oct; 46(5):1412-1417. PubMed ID: 34146432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topiramate extended-release (Trokendi XR) for epilepsy.
    Med Lett Drugs Ther; 2013 Oct; 55(1428):87-8. PubMed ID: 24165709
    [No Abstract]   [Full Text] [Related]  

  • 6. Preparation, Characterization and in vivo Evaluation of Simple Monolithic Ethylcellulose-coated Pellets Containing Topiramate with Biphasic Release Characteristics.
    Gong W; Wang Y; Shao S; Xie S; Shan L; Yang M; Gao C; Zhong W
    Curr Drug Deliv; 2016; 13(2):245-54. PubMed ID: 26563941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.
    Bialer M; Shekh-Ahmad T; Braun TL; Halvorsen MB
    Epilepsia; 2013 Aug; 54(8):1444-52. PubMed ID: 23692553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate.
    Gidal BE; Clark AM; Anders B; Gilliam F
    Epilepsy Res; 2017 Jan; 129():26-32. PubMed ID: 27883934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects.
    Anderson GD; Saneto RP
    CNS Drugs; 2015 Aug; 29(8):669-81. PubMed ID: 26369919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
    Benbadis S; Klein P; Schiemann J; Diaz A; Elmoufti S; Whitesides J
    Epilepsy Behav; 2018 Mar; 80():129-134. PubMed ID: 29414542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures.
    Chung SS; Hogan RE; Blatt I; Lawson P B; Nguyen H; Clark AM; Anders B; Halvorsen MB;
    Epilepsy Behav; 2016 Jun; 59():13-20. PubMed ID: 27084978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate Extended Release: A Review in Epilepsy.
    Hoy SM
    CNS Drugs; 2016 Jun; 30(6):559-66. PubMed ID: 27224993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
    Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ
    Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques.
    Richy FF; Banerjee S; Brabant Y; Helmers S
    Epilepsy Behav; 2009 Oct; 16(2):240-5. PubMed ID: 19699156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study.
    Krymchantowski AV; Jevoux CC
    Headache; 2011 Apr; 51(4):554-8. PubMed ID: 21457240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures.
    Chung SS
    Ther Adv Neurol Disord; 2015 May; 8(3):131-6. PubMed ID: 25941540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study.
    Riesenberg RA; Baldytcheva I; Datto C
    Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from immediate-release to extended-release lamotrigine improves seizure control.
    Ramey P; Osborn M; Abou-Khalil B
    Epilepsy Res; 2014 Nov; 108(9):1637-41. PubMed ID: 25205163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release.
    Ermer JC; Shojaei A; Pennick M; Anderson CS; Silverberg A; Youcha SH
    Curr Med Res Opin; 2007 May; 23(5):1067-75. PubMed ID: 17519073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of topiramate: adverse events and relationships to dosing.
    Shorvon SD
    Epilepsia; 1996; 37 Suppl 2():S18-S22. PubMed ID: 8641242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.